The U.S. Food and Drug Administration has issued an emergency use authorization (EUA) for monoclonal antibody therapy for the treatment of mild-to-moderate COVID-19 in adults and pediatric patients (12 years of age and older weighing at least 40 kilograms [about 88 pounds]) with positive results of direct COVID-19 viral testing and who are at high risk for progression to severe COVID-19, including hospitalization or death.
Monoclonal antibodies are laboratory-made proteins that mimic the immune system’s ability to fight off harmful antigens such as viruses. Sotrovimab is a monoclonal antibody that is specifically directed against the spike protein of COVID-19 and is designed to block the virus’ attachment and entry into human cells.
The EUA allows for monoclonal antibody therapy to be distributed and administered as a 500 milligram single dose intravenously by health care providers. The infusion can last over 30 minutes and you will be observed by your healthcare provider for at least an hour after infusion.
Contact Frontline ER for more information or to see if you qualify.
